Search

Your search keyword '"Raffaella Clerici"' showing total 30 results

Search Constraints

Start Over You searched for: Author "Raffaella Clerici" Remove constraint Author: "Raffaella Clerici"
30 results on '"Raffaella Clerici"'

Search Results

1. A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis

2. Predicted Expenditure for Prescription Drugs for Multiple Sclerosis in the Italian Market Between 2023 and 2028: Results of the Oracle Project

3. Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study

4. Clinical Course and Risk Factors for In-Hospital Mortality of 205 Patients with SARS-CoV-2 Pneumonia in Como, Lombardy Region, Italy

5. Dataset of mRNA levels for dopaminergic receptors, adrenoceptors and tyrosine hydroxylase in lymphocytes from subjects with clinically isolated syndromes

6. The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study

7. The effect of air pollution on COVID‐19 severity in a sample of patients with multiple sclerosis

8. The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study

9. The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study

10. Patients with multiple sclerosis choose a collaborative role in making treatment decision: results from the Italian multicenter SWITCH study

11. Impact of natural menopause on multiple sclerosis: a multicentre study

12. Clinical Course and Risk Factors for In-Hospital Mortality of 205 Patients with SARS-CoV-2 Pneumonia in Como, Lombardy Region, Italy

13. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

14. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context

15. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

16. Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study)

17. Dopaminergic receptors and adrenoceptors in circulating lymphocytes as putative biomarkers for the early onset and progression of multiple sclerosis

18. Two years follow up of domain specific cognitive training in relapsing remitting multiple sclerosis: A randomized clinical trial

19. Risk of Guillain-Barré syndrome after 2010–2011 influenza vaccination

20. A RCT Comparing Specific Intensive Cognitive Training to Aspecific Psychological Intervention in RRMS: The SMICT Study

21. IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease

22. Opposite effects of interferon-beta on new B and T cell release from production sites in multiple sclerosis patients

23. Modulation of the central memory and Tr1-like regulatory T cells in multiple sclerosis patients responsive to interferon-beta therapy

24. Human Schwann Cell Proliferation and IL-6 Production following TNF-α Stimulationin Vitro

25. Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta

26. E-selectin A561C and G98T polymorphisms influence susceptibility and course of multiple sclerosis

27. Visual loss and enlarged extraocular muscles from metastatic signet ring carcinoma

28. Schwann cell apoptosis during cell-mediated demyelination

29. ANTI‐GQ1b ANTIBODIES IN A PATIENT WITH FACIAL NERVE DIPLEGIA WITHOUT OPHTHAMOLPLEGIA

30. Signs and symptoms of COVID-19 in patients with multiple sclerosis

Catalog

Books, media, physical & digital resources